Physician
Pathology Associates of Paducah, PSC
Pathology Associates of Paducah, PSC was paid $1.20M by Medicaid between Jan 2018 and Nov 2024, across 80 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 44% of everything it billed.
33Billing provider infoPATHOLOGY ASSOCIATES OF PADUCAH, PSC
PADUCAH, KY 42003
PADUCAH, KY 42003
33aNPI1679563522assigned 10/24/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.20M
24GClaims240,217
24DCodes billed80
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Kentucky
Rank by total paid#8 of 27
Median peer was paid$139K
This provider vs. median8.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,897 | $184K | |
| 2019 | 22,303 | $99K | |
| 2020 | 27,514 | $104K | |
| 2021 | 35,680 | $184K | |
| 2022 | 48,208 | $222K | |
| 2023 | 52,947 | $238K | |
| 2024incomplete | 27,668 | $165K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 44% | 14,693 | 13,490 | $528K |
| 88307 | 19% | 4,412 | 4,119 | $227K | |
| 80053 | Comprehensive metabolic panel | 6.1% | 30,830 | 21,440 | $73K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5.3% | 3,662 | 3,224 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.3% | 36,087 | 23,506 | $40K |
| 88304 | 3.0% | 4,026 | 3,857 | $36K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.6% | 13,005 | 6,897 | $31K |
| 88141 | 2.1% | 1,815 | 1,720 | $25K | |
| 88342 | 2.0% | 1,113 | 1,013 | $24K | |
| 84484 | <1% | 7,076 | 5,335 | $11K | |
| 83880 | <1% | 2,553 | 2,149 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,148 | 2,859 | $10K |
68 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,532 | $10K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,135 | $7K |
| 83605 | <1% | 4,755 | $7K | |
| 85027 | <1% | 8,748 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,601 | $7K |
| 83735 | <1% | 7,602 | $6K | |
| 87040 | <1% | 2,258 | $6K | |
| 83690 | <1% | 6,844 | $5K | |
| 80061 | Lipid panel | <1% | 1,782 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 808 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,527 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 855 | $4K |
| 85610 | <1% | 6,130 | $4K | |
| 81001 | <1% | 8,789 | $3K | |
| 85730 | <1% | 3,708 | $3K | |
| 82962 | <1% | 6,090 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,202 | $3K |
| 85379 | <1% | 2,139 | $2K | |
| 84703 | <1% | 4,473 | $2K | |
| 82607 | <1% | 852 | $2K | |
| 81025 | <1% | 1,716 | $2K | |
| 80306 | <1% | 2,327 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 826 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,209 | $2K |
| 81003 | <1% | 5,340 | $1K | |
| 82948 | <1% | 3,084 | $1K | |
| 82728 | <1% | 1,007 | $1K | |
| 86140 | <1% | 2,247 | $1K | |
| 84466 | <1% | 828 | $1K | |
| 87081 | <1% | 640 | $1K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 928 | $978.32 |
| 84439 | <1% | 788 | $929.31 | |
| 82803 | <1% | 190 | $900.44 | |
| 82150 | <1% | 352 | $752.26 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,545 | $702.94 |
| 83540 | <1% | 900 | $675.68 | |
| 80074 | <1% | 136 | $650.56 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 610 | $540.94 |
| 87186 | <1% | 145 | $458.81 | |
| 84100 | <1% | 437 | $403.76 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 163 | $333.75 |
| 84145 | <1% | 1,331 | $320.97 | |
| 88312 | <1% | 21 | $233.70 | |
| 82077 | <1% | 2,351 | $230.03 | |
| 82550 | <1% | 234 | $208.54 | |
| 88311 | <1% | 25 | $167.20 | |
| 84702 | <1% | 149 | $144.65 | |
| 87070 | <1% | 47 | $144.22 | |
| 85060 | <1% | 14 | $130.41 | |
| 85652 | <1% | 563 | $110.73 | |
| 87077 | <1% | 31 | $89.73 | |
| 80076 | <1% | 420 | $81.70 | |
| 85651 | <1% | 83 | $79.99 | |
| 85014 | <1% | 294 | $74.23 | |
| 82746 | <1% | 13 | $72.60 | |
| 85018 | <1% | 252 | $65.39 | |
| 87205 | <1% | 63 | $52.70 | |
| 80329 | <1% | 886 | $49.89 | |
| 85007 | <1% | 54 | $36.10 | |
| 87210 | <1% | 88 | $34.92 | |
| 80143 | <1% | 466 | $33.59 | |
| 80179 | <1% | 440 | $31.91 | |
| 83615 | <1% | 69 | $12.87 | |
| 86592 | <1% | 85 | $8.92 | |
| 80354 | 0% | 322 | $0.00 | |
| 87634 | 0% | 26 | $0.00 | |
| 80320 | 0% | 1,124 | $0.00 | |
| 87807 | 0% | 98 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAUGH, ROBERT (PRESIDENT)